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Plasma Lipid Abnormalities in Diabetes Mellitus: 
Observations on HDL Cholesterol and 
Recommendations for the Management of Lipid Abnormalities 
Dorothy Kahkonen, M D * 
T h e manifestations of lipid abnormalities in diabetes 
are variable, as might be expected considering the 
heterogeneous nature of diabetes as well as the com-
plexity of l ipid disorders. The association of hyperl ip id-
emia with diabetic ketoacidosis was first reported by 
Bloor in 1916 (1). Subsequently, the association of 
impaired glucose tolerance with several of the primary 
lipid disorders has been well recognized. Interest in the 
combination of lipid abnormalities and diabetes has 
greatly increased in the past 25 years, along with an 
increasing awareness that the propensity to atheroscle-
rosis is a major threat for the diabetic patient. 
All the now wel l-known lipoproteins and their compo-
nents may participate in the l ipid abnormalities asso-
ciated with diabetes. The least dense l ipoprotein particle 
is the chylomicron f rom exogenous sources; it is com-
posed of as much as 95% triglyceride and serves to trans-
port dietary fat. The very low density l ipoprotein (VLDL) 
particles are primarily endogenous triglycerides synthe-
sized by the liver and small intestine. The enzyme lipo-
protein lipase is responsible for the progressive break-
down of chylomicrons and VLDL to intermediate density 
l ipoproteins (IDL), the remnant triglycerides. The low 
density l ipoprotein (LDL) particles, which transport 
primarily cholesterol, are derived from the metabolism 
of VLDL and are bound and degraded by most extrahe-
patic cells (2). High density l ipoprotein (HDL) particles 
are synthesized in the liver and intestine and seem to 
facilitate the transport and excretion of cholesterol (3). 
In insulin-dependent (Type I) diabetes mellitus, the 
characteristic associated or secondary l ipid disorder is a 
combination of endogenous and exogenous hypertri-
glyceridemia. Elevated plasma lipids result f rom defi-
ciency in the insulin-dependent activity of l ipoprotein 
lipase (LPL). The insulin deficiency which characterizes 
Type I diabetes accounts for decreased LPL activity and 
the consequent inability to metabolize chylomicrons as 
well as VLDL particles. The frequent result is very high 
plasma triglyceride levels, 2,000 to 10,000 mg/d l . 
The most common lipid abnormality in non-insulin-
dependent diabetes (Type II) is endogenous hypertri-
glyceridemia, which is related to overproduct ion of 
VLDL particles. Hypertriglyceridemia is usually mi ld, 
plasma levels reaching only 250 to 500 mg/d l . Type II 
diabetes is characterized by excess caloric intake, hyper-
glycemia,and elevated plasma-free fatty acid concentra-
tions. These conditions stimulate overproduction of 
VLDL. Obesity, increased carbohydrate intake, and 
ingestion of alcohol are all known to contr ibute to t r i -
glyceride formation. 
Elevated serum cholesterol concentration also occurs in 
diabetic patients, but the increases are usually mild to 
moderate. The significance of elevated cholesterol 
appears to depend on the degree of elevation as well as 
the lipoprotein component responsible for the increase— 
VLDL, LDL, or HDL. One possible mechanism for increased 
LDL cholesterol in diabetic persons is disturbed choles-
terol metabolism secondary to glycosylation of LDL. 
Many body proteins are excessively glycosylated in dia-
betics, and the apolipoproteins may be similarly altered. 
Glycosylation interferes with normal l ipoprotein metabo-
lism via LDL receptors. In addit ion, insulin may increase 
cholesterol synthesis by stimulation of the rate-limiting 
enzyme hydroxy-methyl glutaryl Co A reductase (4). 
This mechanism could operate to produce hypercholes-
terolemia when either endogenous or exogenous hyper-
insulinemia is present. 
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Just as l ipid abnormalities occur in many patients with 
diabetes mellitus, disturbed carbohydrate metabolism 
accompanies several of the primary hyperlipidemias. 
This association is characteristic of Type III hyperl ipid-
emia of the Lees and Frederickson classification, also 
termed "broad beta" disease because of its electropho-
retic characteristics (5). In this disorder, impaired glu-
cose tolerance coexists with elevated plasma cholesterol 
concentration and the accumulation of remnant t r i -
glycerides. Secondary hyperlipidemia as endogenous 
hypertriglyceridemia or the combination of endogen-
ous and exogenous hypertriglyceridemia, which charac-
terizes many diabetic patients, is much more common 
than primary hyperlipidemia. In the latter syndrome, 
treatment is directed primarily to the lipid abnormality 
because the impaired glucose tolerance, while of great 
interest, is seldom severe. 
The observed inverse correlation between HDL choles-
terol concentration and the incidence of coronary artery 
disease has stimulated interest in the significance of this 
lipid fraction in patients with increased susceptibility to 
atherosclerosis. Deficient HDL cholesterol concentra-
tions, if found in diabetic patients, could contr ibute to 
macrovascular changes. 
Materials and Methods 
HDL cholesterol concentrations were measured in 453 
diabetic patients, both Type I and Type 11, men and 
women, with and wi thout vascular disease. We com-
pared our patients to 48 normal men and 57 normal 
women, studied concurrently, who had no evidence of 
vascular disease. 
Diabetic patients were classified according to the crite-
ria published by the National Diabetes Data Group (6). 
In this classification, impaired glucose tolerance refers 
to a state of fasting euglycemia in which postprandial 
glucose levels are not normal but are not high enough 
to establish the diagnosis of diabetes mellitus. Type I 
diabetes is insulin dependent, generally characteristic 
of young people and slender adults, whi le Type II dia-
betes is non-insulin dependent, characteristic of over-
weight adults who may or may not require insulin for 
control of symptoms of hyperglycemia. Nevertheless, 
the heterogeneity of the diabetic populat ion and the 
influence of many other known and unknown factors 
on HDL cholesterol concentrations may complicate 
interpretation of these studies. 
Our study population consisted of diabetic patients 
attending the diabetes clinic at Henry Ford Hospital. 
Random or fasting blood samples for total and HDL 
cholesterol determinations were collected during a rou-
tine office visit. Diabetic patients were separated into 
groups with and without vascular disease. We defined 
vascular disease as a history of myocardial infarct ion, 
angina pectoris, cerebrovascular accident, or occlusive 
peripheral vascular disease. 
Normal subjects were healthy colleagues and employees 
who volunteered to serve as normal control subjects. 
They were known not to be diabetic, but family histories 
of diabetes and vascular disease were not obtained. 
HDL cholesterol was measured in serum after precipita-
t ion of LDL and VLDL by the addit ion of dextran sulfate 
and magnesium chloride. Normal values in our labora-
tory are similar to those reported elsewhere, 55 + 14 
mg/d l for women and 45 ± 12 mg/d l for men. 
Results 
In women, HDL cholesterol concentrations f rom normal 
subjects were significantly higher than f rom those with 
diabetes and vascular disease, but did not differ f rom 
those of women with diabetes but no vascular disease. A 
significant difference was demonstrated in HDL concen-
tration between the two diabetic groups, higher levels 
characterizing those wi thout vascular disease (Table I). 
Of 81 diabetic women with vascular disease, 79% had 
HDL cholesterol concentrations below the normal range. 
TABLE I 
HDL Cholesterol Levels in Normal W o m e n (N), Diabetic Women 
wi thout Vascular Disease (DMo) , and Diabetic Women wi th 
Vascular Disease ( D M +) 
Female Subjects 
Normal (57) 
D M o (151) 
DM+ (81) 
HDL Cholesterol 
mg /d l ± SD 
53 ± 13 mg/d l 
49 ± 13 mg /d l 
45 ± 12 mg/d l 
N vs D M o NS 
N vs DM+ p<0.05 
D M o vs DM+ p<0.01 
Although mean HDL concentrations were wi th in the 
normal range for men of all three groups in the study, 
values for the normal subjects presented greater varia-
bility than did those of the diabetic patients but were not 
statistically different from either diabetic group. On the 
other hand, HDL concentration was higher in diabetic 
men without vascular complications than in those so 
af f l ic ted. The di f ference was statistically significant 
(p< .005) (Table II). 
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TABLE II 
HDL Cholesterol Levels in Normal M e n (N), Diabetic M e n wi thout 
Vascular Disease (DMo) , and Diabetic M e n w i th 
Vascular Disease ( D M +) 
HDL Cholesterol Male Subjects 
Normal (48) 
D M o (146) 
D M + (75) 
mg/d l ± SD 
45 ± 15 mg/d l 
4 9 ± 13 mg /d l 
4 3 ± 13 mg/d l 
N vs D M o 
N vs DM+ 
D M o vs DM+ 
NS 
NS 
p<0.005 
Kannel and Castelli (7) suggest that the ratio of total 
cholesterol to HDL cholesterol (TC/HDL) is more impor-
tant than the HDL cholesterol alone in predict ing the 
risk of coronary artery disease. These authors reported 
the significance of these ratios as fol lows: 
One-half average risk 
Women 
3.27 
Men 
3.43 
Average risk 4.44 4.97 
Double average risk 7.05 9.55 
Calculat ion of the TC/HDL ratio for our populat ion con-
firms the significant difference between the normal 
women and diabetic women with vascular disease 
(p<0.01).ln men, a highly significant difference is shown 
between the diabetic groups with and without vascular 
disease (p<0.001), although results in the normal sub-
jects are inconsistent (Table III). 
TABLE III 
Results of Total Cholestero l /HDL Cholesterol Ratios 
Female Subjects 
Normal (57) 
D M o (151) 
DM+ (81) 
Mean ± SD 
4.69 ± 1.60 
5.01 ± 1.87 
5.55 ± 1.77 
N vs D M o 
N vs DM+ 
D M o vs DM+ 
NS 
p<0.01 
p<0.05 
Male Subjects 
Normal (48) 
D M o (146) 
D M + (75) 
Mean + SD 
5.52 ± 2.34 
4.49 ±1.69 
5.52 ± 2.09 
N vs D M o p<0.01 
N vs DM+ NS 
D M o vs DM+ p<0.001 
Discussion 
The populat ion reported isa heterogeneous group with 
both Type I and II diabetes represented. It includes 
patients from 20 to 60 years of age and represents varying 
dee rees of metabolic control. Normal subjects are sim-
ilarly heterogeneous and are distinguished f rom the 
study patients by having neither impaired glucose toler-
ance nor overt vascular disease. Nevertheless, results 
conf i rm that in diabetic patients, as compared to the 
general populat ion, HDL cholesterol concentrations are 
higher in groups wi thout clinical macrovascular disease. 
The presence or absence of diabetes, however, seems 
less relevant to HDL concentration. In other reports, 
HDL cholesterol concentrations apparently correlated 
less well wi th the risk of vascular disease in individuals 
younger than 50 (8) and carried more significance for 
Type 11 than for Type I diabetic patients (9). In addit ion, 
improved metabolic control has been reported to result 
in higher HDL cholesterol levels (10). 
Lipid disorders in diabetic patients should be managed 
very much as the same disorder in nondiabetic patients. 
Improvement in blood glucose levels wil l generally 
lower triglyceride concentrations in insulin-dependent 
diabetics, and several intensive therapeutic regimens 
have demonstrated a decrease in total serum cholesterol 
levels, primarily in LDL cholesterol (11,12). In non-
insulin-dependent diabetic patients, the benefit of care-
ful glycemic control for lowering elevated lipid levels is 
not as readily apparent (13). The most pressing reason for 
control of elevated triglycerides is the risk of acute pan-
creatitis, which is especially prevalent when triglyceride 
levels exceed 1,000 mg/d l . Al though hypertriglycerid-
emia may be associated with the increased incidence of 
atherosclerotic vascular disease, data in this regard 
remain controversial. The Framingham study (14) dem-
onstrated that the fasting level of plasma triglycerides 
did not correlate prospectively with the incidence of 
atherosclerosis. However, other retrospective studies in 
diabetic patients (15) reporta more frequent association 
of atherosclerosis with hypertriglyceridemia than with 
elevated cholesterol concentrations. 
To treat hyperl ipidemia, in diabetic as well as nondia-
betic patients, we recommend a diet with a caloric value 
designed to achieve and maintain ideal body weight. 
The recommended fat content of 30% of total calories 
must be further reduced if chylomicrons are demon-
strated in fasting serum specimens. One half of dietary 
fat should be unsaturated, and cholesterol intake should 
be l imited to 200-300 mg/day. Weight reduction for the 
obese patient cannot be overemphasized as a measure 
to correct l ipid abnormalities. In fact, maintenance of 
body weight 10% below the calculated ideal may be 
necessary to achieve normal plasma triglyceride concen-
tration in some individuals. Dietary carbohydrates should 
be about 50% of the calories, preferably of a complex 
type with increased amounts of fiber. The remaining 
15-20% of calories comes from protein foods. 
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Regular kinetic exercise is widely recommended in the 
therapy of hyperlipidemia. Al though this measure has a 
less direct, less specific effect on plasma lipids, overall 
condit ioning produces considerable benefit, and risk 
factors of vascular disease are demonstrably reduced. 
Lowering of plasma lipid concentrations which may 
occur acutely is often not sustained. However, reduced 
triglyceride and cholesterol levels have been observed 
in non-insulin-dependent diabetics who fol low a regu-
lar exercise program (16). 
Drug therapy for hyperl ipidemia may be recommended 
for diabetic individuals who do not respond to other 
measures. Bile sequestering agents are effective in low-
ering plasma cholesterol concentrations, along with less 
frequently used drugs like nicotinic acid, probucol , and 
d-thyroxin. Clofibrate and nicotinic acid are recom-
mended to control elevated triglycerides in addition to a 
new drug, gemfibrozi l . Side effects (primarily gastroin-
testinal), complications, and marginal effectiveness limit 
the application of currently available drug therapy. The 
occurrence of cholelithiasis and the observed increased 
incidence of gastrointestinal neoplasms associated with 
the use of clofibrate are causes for concern, although 
the relationship is equivocal (17). 
Efforts to increase the level of HDL cholesterol have 
received much attention because o f the potentially pro-
tective effect against coronary heart disease. Increased 
physical activity, weight loss, and stopping cigarette 
smoking are reasonable measures which seem effective. 
Increasing or initiating alcohol consumption is con-
traindicated, despite the experimental evidence that 
HDL cholesterol levels might be increased thereby. 
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